The current invention provides a prophylactic HPV vaccine. Immunization against peptides from the HPV L2 protein gives a robust immune reaction that provides cross-protection against a variety of other high-risk HPV strains. Tha vaccine is based on a thioredoxin-L2 construct and can be produced in standard E. coli bacteria, which makes a cost-effective production feasible.
Further information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
